These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10319345)

  • 1. Radiolabelled somatostatins: towards the magic bullet?
    Buscombe JR; Caplin ME; Mielcarek W
    Nucl Med Commun; 1999 Apr; 20(4):299-301. PubMed ID: 10319345
    [No Abstract]   [Full Text] [Related]  

  • 2. New advances in peptide receptor radionuclide therapy.
    de Jong M; Krenning E
    J Nucl Med; 2002 May; 43(5):617-20. PubMed ID: 11994523
    [No Abstract]   [Full Text] [Related]  

  • 3. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
    Pasieka JL; McEwan AJ; Rorstad O
    Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
    Cybulla M; Weiner SM; Otte A
    Med Sci Monit; 2002 Apr; 8(4):LE7. PubMed ID: 11951054
    [No Abstract]   [Full Text] [Related]  

  • 5. Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.
    Van Binnebeek S; Deroose CM; Baete K; Terwinghe C; Vanbilloen B; Koole M; Haustermans K; Mortelmans L; Verslype C; Van Cutsem E; Verbruggen A; Mottaghy FM
    J Clin Oncol; 2011 Jul; 29(19):e579-81. PubMed ID: 21555687
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
    Breeman WA; de Jong M; Kwekkeboom DJ; Valkema R; Bakker WH; Kooij PP; Visser TJ; Krenning EP
    Eur J Nucl Med; 2001 Sep; 28(9):1421-9. PubMed ID: 11585303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging roles for radiometabolic therapy of tumors based on auger electron emission.
    Mariani G; Bodei L; Adelstein SJ; Kassis AI
    J Nucl Med; 2000 Sep; 41(9):1519-21. PubMed ID: 10994732
    [No Abstract]   [Full Text] [Related]  

  • 9. Yttrium-90-labelled somatostatin-analogue for cancer treatment.
    Otte A; Mueller-Brand J; Dellas S; Nitzsche EU; Herrmann R; Maecke HR
    Lancet; 1998 Feb; 351(9100):417-8. PubMed ID: 9482300
    [No Abstract]   [Full Text] [Related]  

  • 10. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
    Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors.
    Krenning EP; Teunissen JJ; Valkema R; deHerder WW; deJong M; Kwekkeboom DJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):146-50. PubMed ID: 16625865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
    Smith MC; Liu J; Chen T; Schran H; Yeh CM; Jamar F; Valkema R; Bakker W; Kvols L; Krenning E; Pauwels S
    Digestion; 2000; 62 Suppl 1():69-72. PubMed ID: 10940690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience.
    Cremonesi M; Ferrari M; Chinol M; Bartolomei M; Stabin MG; Sacco E; Fiorenza M; Tosi G; Paganelli G
    Q J Nucl Med; 2000 Dec; 44(4):325-32. PubMed ID: 11302260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
    Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
    Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and purification of therapeutic dose of
    Chakravarty R; Chakraborty S; Dash A
    Appl Radiat Isot; 2017 Mar; 121():1-5. PubMed ID: 28012419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The difference between medicine and magic is that magicians know what they are doing.
    Hicks RJ
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):1-4. PubMed ID: 25319711
    [No Abstract]   [Full Text] [Related]  

  • 20. The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy.
    Slooter GD; Aalbers AG; Breeman WA; Hiemstra CA; Marquet RL; Krenning EP; van Eijck CH
    J Nucl Med; 2002 Dec; 43(12):1681-7. PubMed ID: 12468520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.